Alphatec (NASDAQ:ATEC) Lifted to “Buy” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Alphatec (NASDAQ:ATEC) from a hold rating to a buy rating in a research report released on Tuesday, BidAskClub reports.

ATEC has been the topic of a number of other reports. HC Wainwright raised their target price on shares of Alphatec from $4.00 to $6.00 and gave the stock a buy rating in a research report on Tuesday, August 6th. Piper Jaffray Companies assumed coverage on shares of Alphatec in a research report on Monday, August 5th. They set an overweight rating and a $7.00 target price on the stock. Zacks Investment Research upgraded shares of Alphatec from a sell rating to a hold rating in a research report on Monday, May 13th. Finally, ValuEngine upgraded shares of Alphatec from a buy rating to a strong-buy rating in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Alphatec currently has an average rating of Buy and an average target price of $6.50.

ATEC stock opened at $5.73 on Tuesday. The company has a debt-to-equity ratio of 3.59, a current ratio of 2.45 and a quick ratio of 1.40. Alphatec has a twelve month low of $1.18 and a twelve month high of $6.35. The company’s 50 day moving average is $4.87 and its two-hundred day moving average is $3.47.

Alphatec (NASDAQ:ATEC) last released its quarterly earnings data on Wednesday, July 24th. The medical technology company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.05). Alphatec had a negative return on equity of 211.15% and a negative net margin of 45.29%. The company had revenue of $27.32 million for the quarter, compared to analyst estimates of $25.37 million. On average, equities research analysts expect that Alphatec will post -0.91 earnings per share for the current fiscal year.

In related news, CFO Jeffrey G. Black sold 8,929 shares of Alphatec stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $4.75, for a total value of $42,412.75. Following the transaction, the chief financial officer now directly owns 511,862 shares in the company, valued at approximately $2,431,344.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Craig E. Hunsaker sold 100,000 shares of Alphatec stock in a transaction on Monday, August 12th. The shares were sold at an average price of $5.88, for a total transaction of $588,000.00. Following the completion of the transaction, the executive vice president now owns 811,112 shares in the company, valued at $4,769,338.56. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 208,929 shares of company stock worth $1,167,913. Insiders own 34.32% of the company’s stock.

A number of large investors have recently bought and sold shares of ATEC. Dimensional Fund Advisors LP lifted its stake in shares of Alphatec by 8.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 95,662 shares of the medical technology company’s stock valued at $219,000 after acquiring an additional 7,705 shares during the last quarter. Penn Capital Management Co. Inc. bought a new position in Alphatec during the 1st quarter worth $1,261,000. Royce & Associates LP raised its position in Alphatec by 728.6% during the 1st quarter. Royce & Associates LP now owns 290,000 shares of the medical technology company’s stock worth $768,000 after purchasing an additional 255,000 shares during the last quarter. Advisor Group Inc. bought a new position in Alphatec during the 2nd quarter worth $36,000. Finally, JPMorgan Chase & Co. bought a new position in Alphatec during the 2nd quarter worth $36,000. Hedge funds and other institutional investors own 11.55% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures.

Read More: Golden Cross

Receive News & Ratings for Alphatec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alphatec and related companies with MarketBeat.com's FREE daily email newsletter.